Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 10/20 | 0.42 |
| ▸ | FADS1 | O60427 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10266764 | 0.85 | PIP4K2C (0.45) | PIK3CAPIK3CBPIK3CGGRM4FADS1 | |
| SCHEMBL802671 | 0.82 | FADS1 (0.41) | PIK3CAPIK3CBPIK3CGPIK3CDGRM4 | |
| SCHEMBL801648 | 0.81 | SYK (0.44) | PIK3CAPIK3CBPIK3CGPIK3CDGRM4 | |
| SCHEMBL801658 | 0.81 | GRM4 (0.48) | PIK3CAGRM4 | |
| SCHEMBL802679 | 0.80 | GRM4 (0.44) | GRM4 | |
| SCHEMBL802329 | 0.77 | VCP (0.38) | GRM4FADS1ADRA2ATRPA1 | |
| SCHEMBL802674 | 0.77 | GSK3A (0.44) | PIK3CAPIK3CBPIK3CGPIK3CDGRM4 | |
| SCHEMBL13055191 | 0.76 | PIK3CA (0.37) | PIK3CAPIK3CBPIK3CGGRM4FADS1 | |
| SCHEMBL802280 | 0.76 | FADS1 (0.42) | PIK3CAPIK3CBPIK3CGPIK3CDGRM4 | |
| SCHEMBL802326 | 0.76 | FADS1 (0.48) | PIK3CAPIK3CBPIK3CGPIK3CDGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | PIK3CA 246/4885PIK3CB 476/4885PIK3CG 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.